PARIS, July 26, 2024 /PRNewswire/ -- MGI Tech Co., Ltd.
("MGI"), a company committed to building core tools and
technologies that drive innovation in life science, today announced
its collaboration with renowned geneticist, Professor Yannis Pitsiladis from Hong Kong Baptist University, on sports and anti-doping
research. Utilizing MGI's state-of-the-art DNBSEQ sequencers and
automation platforms, the collaboration will leverage the power of
omics to detect drugs in sport with reference to blood doping.
"With an estimated 6% of top athletes worldwide using doping,
more sophisticated methods of detection are required to stamp out
this unethical practice," said Prof. Pitsiladis, a pioneer in
anti-doping research and a member of the International Olympic
Committee Medical and Scientific Commission. "High throughput
sequencing could play a vital role in spotting blood doping, the
method used and even when it took place. MGI's advanced sequencing
tools are helping to optimize what was once a labor-intensive,
costly, and time-consuming process."
As the Paris 2024 Summer
Olympics commence, Prof. Pitsiladis, invited by the World Olympians
Association (WOA), will showcase his research and participate in a
panel discussion, as part of Hong Kong Baptist
University's two-day program during the games, taking place
on 29 July at OLY House Paris 2024 @ Caisse d'Epargne.
Additionally, MGI will exhibit its cutting-edge portable DNBSEQ-E25
sequencer, ultra-high speed DNBSEQ-G99 platform, and AlphaTool
automated pipetting robot at the venue, offering Olympians from
around the world a glimpse of the advanced technologies.
On July 22, Prof. Pitsiladis, in
conjunction with MGI and other international researchers, published
a perspective article titled "Practical steps to develop a
transcriptomic test for blood doping" on Translational Exercise
Biomedicine. Outlining considerations for developing a
transcriptomic test for blood doping, the article serves to assist
international research and anti-doping centers in adopting
transcriptomic testing in compliance with the World Anti-Doping
Agency.
"We are proud to empower valuable research into sports
performance and anti-doping testing through omics and showcase our
technologies at one of the most important events in sports,"
said Duncan Yu, President of MGI.
"With intelligent innovation at the heart of MGI, we are committed
to applying our technologies to enable significant advancements and
support groundbreaking applications in this field."
About MGI
MGI Tech Co., Ltd. (or its subsidiaries, together referred to
MGI) is committed to building core tools and technologies that
drive innovation in life science. Our focus lies in research &
development, manufacturing, and sales of instruments, reagents, and
related products in the field of life science and
biotechnology. We provide real-time, multi-omics, and full
spectrum of digital equipment and systems for precision medicine,
agriculture, healthcare and various other industries. Founded in
2016, MGI has grown into a leader in life science, serving
customers across six continents and have established research,
manufacturing, training, and after-sales service facilities
globally. MGI stands out as one of the few companies capable of
independently developing and mass-producing clinical-grade gene
sequencers with varying throughput capacities, ranging from Gb to
Tb levels. With unparalleled expertise, cutting-edge products, and
a commitment to global impact, MGI continues to shape the
trajectory of life sciences into the future. To learn more, please
visit https://en.mgi-tech.com/, LinkedIn, X, and YouTube.
Logo
- https://mma.prnewswire.com/media/2329841/MGI__Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/mgi-and-hkbu-collaborate-on-advanced-sequencing-technology-to-combat-doping-in-sports-302207425.html